Rheumatoid Arthritis
11
Companies
17
Drug Programs
5
Phase 3
0
Upcoming PDUFAs
Coherus Oncology, Inc.
Etanercept
Eli Lilly and Company
cDMARD
Gilead Sciences, Inc.
MTX
Amgen Inc.
Etanercept Liquid
Sanofi
Sulfasalazine
Ionis Pharmaceuticals, Inc.
ISIS 104838
Aclaris Therapeutics, Inc.
ATI-450
AnaptysBio, Inc.
Rosnilimab
Galapagos NV
GLPG0259 oral capsule
Galapagos NV
GLPG0634
Ionis Pharmaceuticals, Inc.
ISIS CRP Rx or Placebo
Galapagos NV
Placebo
Galapagos NV
GLPG3970
XBiotech Inc.
Natrunix
Vertex Pharmaceuticals Incorporated
VX-702
Vertex Pharmaceuticals Incorporated
VX-509
Aclaris Therapeutics, Inc.
ATI-450 50 mg oral tablet BID
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| CHRS Coherus Oncology, Inc. | Etanercept | Phase 3 | — | — | — |
| LLY Eli Lilly and Company | cDMARD | Phase 3 | — | — | — |
| GILD Gilead Sciences, Inc. | MTX | Phase 3 | — | — | — |
| AMGN Amgen Inc. | Etanercept Liquid | Phase 3 | — | — | — |
| SNY Sanofi | Sulfasalazine | Phase 3 | — | — | — |
| IONS Ionis Pharmaceuticals, Inc. | ISIS 104838 | Phase 2 | — | — | — |
| ACRS Aclaris Therapeutics, Inc. | ATI-450 | Phase 2 | — | — | — |
| ANAB AnaptysBio, Inc. | Rosnilimab | Phase 2 | — | — | — |
| GLPG Galapagos NV | GLPG0259 oral capsule | Phase 2 | — | — | — |
| GLPG Galapagos NV | GLPG0634 | Phase 2 | — | — | — |
| IONS Ionis Pharmaceuticals, Inc. | ISIS CRP Rx or Placebo | Phase 2 | — | — | — |
| GLPG Galapagos NV | Placebo | Phase 2 | — | — | — |
| GLPG Galapagos NV | GLPG3970 | Phase 2 | — | — | — |
| XBIT XBiotech Inc. | Natrunix | Phase 2 | — | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | VX-702 | Phase 2 | — | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | VX-509 | Phase 2 | — | — | — |
| ACRS Aclaris Therapeutics, Inc. | ATI-450 50 mg oral tablet BID | Phase 2 | — | — | — |
Not Financial Advice
All predictions are probabilistic and based on historical data. Past performance does not guarantee future results. Consult a qualified financial advisor.